Lenvatinib

Generic Name
Lenvatinib
Brand Names
Lenvima 10, Kisplyx, Lenvima
Drug Type
Small Molecule
Chemical Formula
C21H19ClN4O4
CAS Number
417716-92-8
Unique Ingredient Identifier
EE083865G2
Background

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.

Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

Indication

Lenvatinib is indicated for the treatment of the following cancerous conditions:

Differentiated Thyroid Cancer (DTC)

Renal Cell Carcinoma (RCC)

Hepatocellular Carcinoma (HCC)

Endometrial Carcinoma

Associated Conditions
Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
Associated Therapies
-

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

First Posted Date
2019-12-24
Last Posted Date
2024-08-20
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
64
Registration Number
NCT04209660
Locations
🇺🇸

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

🇺🇸

Baptist Alliance MCI, Miami, Florida, United States

🇺🇸

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States

and more 5 locations

A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2019-12-20
Last Posted Date
2024-02-14
Lead Sponsor
Melanoma Institute Australia
Target Recruit Count
21
Registration Number
NCT04207086
Locations
🇦🇺

Melanoma Institute Australia, North Sydney, New South Wales, Australia

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

First Posted Date
2019-12-13
Last Posted Date
2024-08-23
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
511
Registration Number
NCT04199104
Locations
🇨🇦

Princess Margaret Cancer Centre ( Site 0200), Toronto, Ontario, Canada

🇺🇸

University of Connecticut Health Center ( Site 0020), Farmington, Connecticut, United States

🇺🇸

Dana Farber Cancer Institute ( Site 0019), Boston, Massachusetts, United States

and more 149 locations

Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

First Posted Date
2019-12-10
Last Posted Date
2024-06-18
Lead Sponsor
Centre Leon Berard
Target Recruit Count
77
Registration Number
NCT04193553
Locations
🇫🇷

Institut de Cancérologie de Lorraine Alexis Vautrin, Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France

🇫🇷

Hopital de La Timone, Marseille, Bouches Du Rhône, France

🇫🇷

Centre Antoine LACASSAGNE, Nice, Alpes-Maritimes, France

and more 11 locations

Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis

First Posted Date
2019-11-20
Last Posted Date
2021-02-23
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
25
Registration Number
NCT04170179
Locations
🇨🇳

Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma

First Posted Date
2019-11-19
Last Posted Date
2019-11-19
Lead Sponsor
RenJi Hospital
Target Recruit Count
108
Registration Number
NCT04168944

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

First Posted Date
2019-11-15
Last Posted Date
2024-12-16
Lead Sponsor
BeiGene
Target Recruit Count
300
Registration Number
NCT04164199
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

🇨🇳

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China

and more 70 locations

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

First Posted Date
2019-11-06
Last Posted Date
2024-07-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
81
Registration Number
NCT04154189
Locations
🇺🇸

Loma Linda University Medical Center, Loma Linda, California, United States

🇺🇸

University of Mississippi Medical Center, Jackson, Mississippi, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 81 locations

The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)

First Posted Date
2019-08-13
Last Posted Date
2019-08-13
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
206
Registration Number
NCT04053985
Locations
🇨🇳

SUN YAT-SEN University Cancer Center, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath